On October 22, 2015, Hirayama, Takaharu; Fujimoto, Jun; Cary, Douglas Robert; Okaniwa, Masanori; Hirata, Yasuhiro published a patent.HPLC of Formula: 428855-17-8 The title of the patent was Preparation of heterocyclic compounds as cyclin-dependent protein kinase inhibitors for prophylactic and therapeutic treatment of cancer. And the patent contained the following:
The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula I [R1-R3, R5a, R5b, R7, R8 = H, substituent; R4 = (un)substituted heteroaryl; R5a and R5b may be bonded to form double bond or C3-4 cycloalkyl; R7 and R8 may be bonded to form N-containing heterocyclyl] or a salt thereof. Thus, (2E)-N-[4-[2-(1,3,4-oxadiazol-2-yl)ethyl]phenyl]-3-[4-(2-thienyl)pyridin-3-yl]acrylamide (preparation given) inhibited CDK8 and CDK19 activity with inhibitory rates of 101 and 100%, resp. at 1 μM and inhibited RPMI8226 cell proliferation with inhibitory rate of 59% at 1 μM. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).HPLC of Formula: 428855-17-8
The Article related to preparation heterocycle cyclin dependent protein kinase inhibitor antitumor, pyridine preparation cdk8 cdk19 inhibitor antitumor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 428855-17-8
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts